Transcatheter Aortic Valve Replacement (TAVR) Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative and qualitative market trends within Cardiovascular Devices therapeutic area.
Transcatheter Aortic Valve Replacement (TAVR), also known as, Transcatheter Aortic Valve Implantation (TAVI), is a minimally invasive procedure used to treat severe aortic valve stenosis by implanting a Transcatheter Heart Valve in a patient's diseased aortic valve. The procedure is largely performed transfemorally (through the groin) but can also be performed via alternative pathways including the transapical, transaortic, transcarotid, transsubclavian and transcaval approaches.
Transcatheter aortic valve implantation is used in patients who are elderly or are at a high risk for surgery and have severe symptomatic aortic valve stenosis. The number of patients who suffer from aortic stenosis is steadily increasing due to changing demographics. While aortic valve replacement remains the gold standard therapy, transcatheter aortic valve replacement, also known as transcatheter aortic valve implantation has been identified as an alternative in elderly patients, inoperable or of higher surgical risk, and its suitability as a replacement for surgical aortic valve implantation is being explored due to lower operation and recovery times.
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Companies covered: Edwards Lifesciences, Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, MicroPort Scientific Corp, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Transcatheter Aortic Valve Replacement (TAVR), also known as, Transcatheter Aortic Valve Implantation (TAVI), is a minimally invasive procedure used to treat severe aortic valve stenosis by implanting a Transcatheter Heart Valve in a patient's diseased aortic valve. The procedure is largely performed transfemorally (through the groin) but can also be performed via alternative pathways including the transapical, transaortic, transcarotid, transsubclavian and transcaval approaches.
Transcatheter aortic valve implantation is used in patients who are elderly or are at a high risk for surgery and have severe symptomatic aortic valve stenosis. The number of patients who suffer from aortic stenosis is steadily increasing due to changing demographics. While aortic valve replacement remains the gold standard therapy, transcatheter aortic valve replacement, also known as transcatheter aortic valve implantation has been identified as an alternative in elderly patients, inoperable or of higher surgical risk, and its suitability as a replacement for surgical aortic valve implantation is being explored due to lower operation and recovery times.
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are :
Currently marketed Transcatheter Aortic Valve Replacement Devices (TAVR) and evolving competitive landscape :
- Insightful review of the key industry trends.
- Annualized total Transcatheter Aortic Valve Replacement (TAVR) Devices market revenue by segment and market outlooks from 2015-2033.
- Granular data on total procedures, units, average selling prices and market values by segment.
Global, Regional and Country level market specific insights :
- Qualitative market specific information is available with global trends further broken down into regional trends. In addition the analyst analysts provide unique country specific insights on the market.
- SWOT analysis for Transcatheter Aortic Valve Replacement (TAVR) Devices market.
- Competitive dynamics insights and trends provided for Transcatheter Aortic Valve Replacement (TAVR) Devices market.
- Country specific overview of the healthcare system.
- Country specific reimbursement policies.
- Country specific medtech regulatory landscape.
Companies covered: Edwards Lifesciences, Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, MicroPort Scientific Corp, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Scope
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for :- CMO executives who must have deep understanding of the Transcatheter Aortic Valve Replacement (TAVR) Systems marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to :
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
- Develop business strategies by understanding the trends shaping and driving Transcatheter Aortic Valve Replacement (TAVR) market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Transcatheter Aortic Valve Replacement (TAVR) market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific Transcatheter Aortic Valve Replacement (TAVR) market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Edwards Lifesciences Corp
- Medtronic Plc
- Abbott Laboratories
- Boston Scientific Corp
- MicroPort Scientific Corp